TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01655173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Description: The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational activity intervention
Description: The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
Study: NCT01591499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOFINITY® MF - AIR OPTIX® AQUA MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOFINITY® MF - AIR OPTIX® AQUA MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOFINITY® MF - PUREVISION® MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOFINITY® MF - PUREVISION® MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
Study: NCT04288739

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometric immunophenotyping
Description: Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).

Intervention type: GENETIC
Intervention: Xist gene by fluorescence insitu hybridization
Description: Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes.
Study: NCT01256086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formatris 24µg
Description: 12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formatris 12µg
Description: 12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil P 24µg
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil P 12µg
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
Study: NCT03037918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult light
Description: A fermented milk drink containing the probiotic Lactobacillus casei Shirota
Study: NCT02204449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Peer Mentorship
Study: NCT01912547

Intervention type: PROCEDURE
Intervention: Blood draw for TEG analysis
Description: Blood drawn for TEG analysis
Study: NCT01556464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-adjusting CPAP
Description: A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
Study: NCT00422916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Study: NCT01269918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
Study: NCT03190707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed.
Study: NCT04450316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 4.5mg tab (low-dose) nightly
Study: NCT01269918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
Study: NCT00544596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT01279824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention
Study: NCT00439985

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
Study: NCT04319471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/S-1
Description: Drug: Capecitabine/S-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Head and neck radiotherapy
Description: IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Consolidative Therapy
Description: radiotherapy，surgery or interventional therapy for all metastatic sites.
Study: NCT00544596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT00259857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
Study: NCT04450316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab nightly
Study: NCT02496442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueduct
Description: Using Aqueduct in procedures to continuously supply the irrigation solutions
Study: NCT00259857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
Study: NCT03704181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG twice day for one year
Description: placebo twice day for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo twice day for one year
Study: NCT04406805

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of plasma and urine trimethylamine-N-oxide concentration
Description: Information already included in arm/group descriptions.
Study: NCT01527786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: 50mg-100mg everyday for 12 weeks over 7 study visits
Study: NCT04045665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet-only strategy
Description: Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant plus background antiplatelet therapy
Description: OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study: NCT03958877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a)
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta type 1a
Description: Administered as specified in the treatment arm
Study: NCT04990726

Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Undergo medical assessments

Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Undergo medical assessments

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03518320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Study: NCT01785602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: Capsules
Study: NCT00461396

Intervention type: DRUG
Intervention: Interferon-1beta (Betaseron, BAY86-5046)
Description: Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
Study: NCT02251431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYDUREON
Description: Exenatide-extended release, Cohorts A and B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort A only
Study: NCT01136941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
Study: NCT01785602

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT03811366

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid monotherapy
Description: Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
Study: NCT02143479

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT03694483

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis for the detection of prostasomes
Description: Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis for the detection of prostasomes
Description: Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing.
Study: NCT04141761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: This group will receive Visbiome probiotic in powder form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a placebo in powder form.
Study: NCT01246102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
Study: NCT00003861

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT02928991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for Acquired AA
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0
Study: NCT06155617

Intervention type: OTHER
Group type: OTHER
Intervention: Upper Extremity Rehabilitation
Description: Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
Study: NCT02526992

Intervention type: DEVICE
Group type: OTHER
Intervention: HR-pQCT
Description: HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
Study: NCT02928991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0
Study: NCT03026894

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Panoramic Radiograph
Description: Measurement of bone resorption

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Panoramic Radiograph
Description: Measurement of bone resorption

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan III occlusal system
Description: Recording percentage of force in maximum intercuspation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan III occlusal system
Description: Recording percentage of force in maximum intercuspation
Study: NCT01849029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Cognitive
Description: Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Processing Therapy-Cognitive
Description: Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
Study: NCT03630926

Intervention type: DIAGNOSTIC_TEST
Intervention: NV-VPAC1 PCa Urine Diagnostic Test
Description: The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: NV-VPAC1 PCa Urine Diagnostic Test
Description: The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: NV-VPAC1 PCa Urine Diagnostic Test
Description: The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
Study: NCT06244329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.